{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:35:55Z","timestamp":1790667355880,"version":"4.1.0"},"reference-count":14,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2005,9,7]],"date-time":"2005-09-07T00:00:00Z","timestamp":1126051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2006,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We report on a 30\u2010year\u2010old patient with advanced cerebellar degeneration due to SCA2. He presented with severe myoclonus, which was resistant to conventional therapy and dramatically improved after administration of 12\u201318 gm\/die piracetam. Piracetam may be considered in the treatment of refractory myoclonus in spinocerebellar degenerations. \u00a9 2005 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.20683","type":"journal-article","created":{"date-parts":[[2005,9,7]],"date-time":"2005-09-07T20:46:36Z","timestamp":1126125996000},"page":"116-118","source":"Crossref","is-referenced-by-count":15,"title":["Suppression of myoclonus in SCA2 by piracetam"],"prefix":"10.1002","volume":"21","author":[{"given":"Anna","family":"De Rosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Striano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"De Falco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tecla","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Striano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Filla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"De Michele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,9,7]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng1196-269"},{"key":"e_1_2_5_3_2","volume-title":"Baker and Joynt's clinical neurology on CD\u2010ROM","author":"Coppola G","year":"2004"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870110615"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870080112"},{"key":"e_1_2_5_6_2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0022-510X(96)00231-6","article-title":"International cooperative ataxia rating scale for pharmacological assessment of the cerebellar syndrome: the Ataxia Neuropharmacology Committee of the World Federation of Neurology","volume":"145","author":"Trouillas P","year":"1997","journal-title":"J Neurol Sci"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.60.12.1749"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004150170245"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20234"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(04)00880-4"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.48.6.506"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(96)00463-7"},{"key":"e_1_2_5_13_2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1684\/j.1950-6945.2000.tb00363.x","article-title":"Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profile","volume":"2","author":"Genton P","year":"2000","journal-title":"Epileptic Disord"},{"key":"e_1_2_5_14_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1684\/j.1950-6945.2000.tb00445.x","article-title":"Antimyoclonic effect of levetiracetam","volume":"2","author":"Genton P","year":"2000","journal-title":"Epileptic Disord"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10364"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.20683","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T14:19:32Z","timestamp":1760969972000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.20683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,7]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["10.1002\/mds.20683"],"URL":"https:\/\/doi.org\/10.1002\/mds.20683","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9,7]]}}}